CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发淋巴瘤中双特异性抗体疗法或 CAR-T 细胞治疗的选择
英文原题：Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
查看英文原题
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性（R/R）侵袭性B细胞非霍奇金淋巴瘤患者历来生存结局较差，CAR-T 细胞疗法如今为其中一部分患者提供了治愈机会。然而，数种具有显著活性的创新双特异性单克隆抗体（BsAb）疗法已获批用于R/R侵袭性大B细胞淋巴瘤（LBCL），患者和肿瘤科医生将面临如何根据患者及疾病相关因素安排CAR-T 与BsAb治疗顺序的决策。本文综述比较CAR-T 与BsAb治疗R/R LBCL的资料，着重介绍各治疗模式的疗效及毒性证据，并提出安排这些高效疗法使用顺序的路线图。
展开英文摘要原文
Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of those patients.
However, with the approval of several novel bispecific monoclonal antibody (BsAb) therapies with considerable activity in R/R aggressive large B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions regarding how to sequence CAR-T and BsAb therapies based on patient- and disease-related factors. In this review, we compare CAR-T and BsAb therapies for R/R LBCL, highlighting data on the efficacy and toxicity of each treatment paradigm, and provide a roadmap for sequencing these highly effective therapies.
论文信息
- 作者
- Major A、Kamdar M
- 单位
- Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
- 文献类型
- 综述
- 期刊
- Hematology. American Society of Hematology. Education Program2023 Dec 8
- 原文标识
- PubMed 38066907 · DOI 10.1182/hematology.2023000438
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →